ClinicalTrials.gg
CompletedNCT00317239Updated Feb 20, 2018Results posted

VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

A Phase 3 interventional study of Ferrous Sulfate tablets and Ferric Carboxymaltose (FCM) in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.

Enrollment
17th of 54
255 · median 156
Started
2005
with 4 others
Phase 3
23 of 54
none open now
Registered
1st of 54
by date
Lead sponsor
11 of 54
American Regent, Inc.

Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 17th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 1st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing ferric carboxymaltose in Anemia, or all of them as a file.
02

Study summary

This study compares the efficacy and safety of intravenous (IV) iron (VIT45) versus oral iron (ferrous sulfate) administered to subjects who suffer from anemia and are diagnosed with non-dialysis dependent chronic kidney disease (NDD-CKD).

Read the detailed description

This study compares the efficacy and safety of intravenous (IV) iron (VIT45) versus oral iron (ferrous sulfate) administered to subjects who suffer from anemia and are diagnosed with non-dialysis dependent chronic kidney disease (NDD-CKD).

03

Conditions studied

  • Anemia

Keywords

  • Anemia
  • Chronic Kidney Disease
  • Iron
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females > or = 12 years of age
  • NDD-CKD subjects
  • Baseline \< or = 11g/dl
  • Stable erythropoietin (EPO) status

Exclusion criteria

Exclusion Criteria:

  • Known to ferrous sulfate or IV iron
  • Unstable EPO status
  • Anemia not related to CKD
  • Chronic, serious infection
  • Recent IV iron
  • Recent blood transfusion
  • Recent blood loss
  • Need for surgery
  • Received drug within 30 days
  • Female subjects who are pregnant or lactating
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose (FCM)

    A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.

    Drug: Ferric Carboxymaltose (FCM)

  • Active comparator
    Ferrous Sulfate tablets

    325 mg/TID x 8 weeks

    Drug: Ferrous Sulfate tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL

    Time frame: anytime during the study

07

Results

Posted Nov 25, 2013

Participant flow

Hospitals and medical clinics

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM)Ferrous Sulfate Tablets
Started147103
Completed13484
Not completed1319

Outcome measures

PrimaryNumber of Subjects Achieving an Increase in Hemoglobin ≥1g/dL
Time frame:
anytime during the study
Reported as:
Number · participants
Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL
participantsFerric Carboxymaltose (FCM)Ferrous Sulfate Tablets
Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL8735

Adverse events

Collected over 1 year and 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)—13/147 (8.8%)11/147 (7.5%)
Ferrous Sulfate Tablets—10/103 (9.7%)20/103 (19.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventFerric Carboxymaltose (FCM)Ferrous Sulfate Tablets
Gastrointestinal hemorrhageGastrointestinal disorders0/1472/103
Renal failure chronicRenal and urinary disorders0/1472/103
Cardiac failure congestiveCardiac disorders2/1471/103
Coronary artery diseaseCardiac disorders2/1470/103
Myocardial ischemiaCardiac disorders0/1471/103
Intestinal hemorrhageGastrointestinal disorders0/1471/103
HyperkalemiaMetabolism and nutrition disorders0/1471/103
Cerebrovascular accidentNervous system disorders0/1471/103
Glomerulonephritis proliferativeRenal and urinary disorders0/1471/103
DyspneaRespiratory, thoracic and mediastinal disorders0/1471/103
Most frequent other events
Most frequent other events
EventFerric Carboxymaltose (FCM)Ferrous Sulfate Tablets
ConstipationGastrointestinal disorders2/14718/103
Odema peripheralGeneral disorders9/1472/103

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ferric Carboxymaltose (FCM)Ferrous Sulfate TabletsTotal
<=18 years000
Between 18 and 65 years6542107
>=65 years8261143
Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM)Ferrous Sulfate TabletsTotal
Mean65.4 ± 12.5666.8 ± 13.4865.94 ± 12.94
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)Ferrous Sulfate TabletsTotal
Female9473167
Male533083
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM)Ferrous Sulfate TabletsTotal
United States147103250
08

Study locations

1 site
  • Luitpold Pharmaceuticals
    Norristown, Pennsylvania 19403, United States
09

References and documents

Publications

  • Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011 May;26(5):1599-607. doi: 10.1093/ndt/gfq613. Epub 2010 Oct 7. PubMed 20929915 ↗
  • Qunibi W, Martinez C, Smith M, Benjamin J, Dinh Q. A Randomized Controlled Trial Comparing IV Ferric Carboxymaltose (FCM) to Oral Iron in Anemic Patients with Non-Dialysis-Dependent CKD. American Society of Nephrology Renal Week 2007.
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Feb 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 6 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2006
First posted
Apr 24, 2006
Start
May 2005
Primary completionActual
Feb 2007
CompletionActual
Aug 2007
Results first posted
Nov 25, 2013
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00317239
Responsible party
Sponsor
First posted
Apr 24, 2006
Start date
May 2005
Primary completion
Feb 2007
Completion
Aug 2007
Results posted
Nov 25, 2013
Last update
Feb 20, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion